SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven
|
|
- Gilbert Garrett
- 5 years ago
- Views:
Transcription
1 Bradford, Airedale, Wharfedale & Craven Managed Clinical Network SYMPTOM CONTROL IN THE LAST DAYS OF LIFE Guidelines for Healthcare Professionals Bradford, Airedale, Wharfedale & Craven Signs and symptoms that suggest someone may be entering the last days of life: (NB for patients with an underlying progressive condition the background of a gradual deterioration over weeks/months is important) Sleepiness, difficulty waking, generalised weakness (conscious level may be reduced or patient may become unconscious) Difficulty swallowing (including medication), reduced interest in eating and drinking Loss of control of bladder and bowel function Restless movements (as though in pain) Changes in breathing pattern Noisy breathing Cold feet, hands, legs and arms Confusion and disorientation It is important to identify any potentially reversible causes for the patient s deterioration (the decision about how appropriate it will be to investigate and/or treat these should be discussed with the patient/family and the MDT) Potentially reversible causes to consider includes: Dehydration Infection Opioid toxicity Steroid withdrawal Adverse effect of other drugs Acute kidney Injury (AKI) Delirium Hypercalcaemia Constipation Hypo or hyperglycaemia
2 Fundamental to the practice of palliative care is an emphasis on individualised care for the patient. If symptoms fail to respond to usual measures, or if you are concerned that the recommendations given here may not be appropriate to the clinical situation, please contact your local Specialist Palliative Care Team (SPCT). SPCT advice can be sought from: Working hours (Mon-Fri 8am-5pm): BTHFT Inpatients: Hospital Palliative Care Team or #6479 / #6435 / #6571 ANHSFT Inpatients: Hospital Palliative Care Team or bleep 3148 / 3242 Bradford Community (inc Community Hospitals /Care Homes): Community Palliative Care Team Airedale, Craven and Wharfedale Community (inc care homes): Community Palliative Care Team Out of Hours: Contact On-call Consultant in Palliative Medicine via Marie Curie Hospice ( ) or Manorlands Hospice ( ) On Call CNS (7 day Airedale, Wharfedale and Craven ONLY) or bleep 3148 Key Prescribing Points This guidance is about managing symptoms in the last days of life when it is clear that the patient is dying. The following should be considered when prescribing for dying patients: 1. ANTICIPATORY OR AHEAD OF TIME PRN MEDICATION All patients should have as required (PRN) medication for symptom control prescribed, which includes: medication for the relief of pain, nausea/vomiting, restlessness, shortness of breath and respiratory tract secretions before they occur, unless there are contraindications. This means that symptoms can be controlled without delay even if they arise overnight. Where a dose range has been prescribed, start with the lowest dose and assess benefit. If patients require more than 2 doses in 6 hours, staff should seek medical advice. Examples of appropriate medication for anticipatory as required prescribing: Opioid analgesic subcutaneous (SC), hourly as required; dose depends on the patient, clinical problem and previous opioid use. 1/6th of 24 hour dose of any regular opioid. If not on a regular opioid, prescribe morphine sulphate SC 2.5mg to 5mg hourly. Anxiolytic sedative: midazolam SC 2.5mg to 5mg, hourly. Anti-secretory medication: hyoscine butylbromide (Buscopan) SC 20mg, hourly. Anti-emetic: haloperidol 1.5mg SC, 12 hourly. 2. ONCE THE ORAL ROUTE IS LOST. Think About: Is the medicine still needed? Consider if medication is still needed for comorbidities (see page 6) Non-opioid analgesia e.g. paracetamol, antidepressants, anti-epileptics can usually be stopped when oral route is lost: continuing opioids is usually sufficient. Anticonvulsants for seizures should be continued via an alternative route (see page 6). Is there an alternative route? Most opiates will have an alternative SC route Is a syringe pump required to administer necessary medications subcutaneously? A syringe pump is used not only to replace existing medication (e.g. regular MST Continus) but is titrated where necessary to take account of additional (PRN) medication 3. PROBLEMS TO CONSIDER Managing uncontrolled symptoms see page 3 onwards Managing acute and distressing terminal events see page 6 4. REVIEW AND ASSESS BENEFIT OF ANY INTERVENTIONS Review September
3 PAIN Opioid analgesics must NOT be used to sedate dying patients Sudden increase in pain: exclude urinary retention, constipation or other reversible cause. Paracetamol or Non-Steroidal Anti-Inflammatory Drugs (NSAID) (as liquid/dispersible). NSAID benefits may outweigh risks in a dying patient; can help bone, joint, pressure sore, inflammatory pain. If unable to manage via oral route and still requires NSAID, seek specialist If not on any regular opioid, prescribe PRN morphine SC 2.5mg 5mg as per anticipatory guidance If unable to manage oral medication, or requiring more than 2 doses PRN over 24 hours, convert the total 24 hour oral morphine to a 24 hour, SC infusion: Divide the TOTAL daily dose of oral morphine by 2. e.g. oral morphine 30mg = SC morphine 15mg /24hrs If already on oral oxycodone use SC oxycodone. Divide TOTAL daily dose of oral oxycodone by 2 e.g. oral oxycodone 15mg = SC oxycodone 7.5mg /24hrs Breakthrough (PRN) analgesia should be prescribed hourly as required: 1/6th of total 24 hour dose of any regular opioid, both orally and subcutaneous equivalent dose Total daily dose of oral Equivalent total daily PRN oral morphine dose PRN sc morphine dose morphine dose of sc morphine 60mg 30mg 10mg 5mg If patient is already using FENTANYL or BUPRENORPHINE transdermal patches, these should be continued in dying patients. If they have been requiring additional PRN opioid on a regular basis, with benefit, this can be added to a syringe pump. Ensure that both patch and pump dose are taken into account when calculating appropriate breakthrough dose. For patients with stage 4-5 chronic kidney disease, severe liver failure or elderly: - Use opioids cautiously. - Smaller doses will be required - Length of action will be increased (e.g. by 12 hours or more) - Continuous infusions are seldom required. - Opioids other than morphine may be better tolerated. Seek specialist advice AGITATION / DELIRIUM Sudden increases in agitation; exclude urinary retention, constipation or other reversible cause Consider a nicotine replacement patch in heavy smokers who may have withdrawal symptoms. NB: If requiring more than 2 doses of PRN medication in 24 hours, consider starting a 24 hour SC infusion via syringe pump.. Anxiety / distress Confusion / delirium Prolonged terminal delirium/ distress with no reversible causes midazolam SC 2.5mg to 5mg, PRN hourly haloperidol SC 0.5mg to 1.5mg, once or twice daily PRN (caution in elderly, give reduced dose) 1st line midazolam SC 10mg to 30mg (depending on previous 24hr requirements) and/or Haloperidol 3mg to 5mg over 24 hours in a syringe pump + midazolam SC 5mg PRN hourly, as required 2nd line Seek Specialist Palliative Care Advice If symptoms persist and you are unsure what to do or are concerned about side effects: seek specialist Review September
4 NAUSEA and /or VOMITING (last days of life) If already controlled with an oral antiemetic New nausea & vomiting 1 st line SC INJECTION 24HR SYRINGE PUMP PRN haloperidol SC 1.5mg up to 12 hourly, or 1.5mg to 3mg once daily (caution in elderly) Use the same drug in a SC infusion (e.g. metoclopramide, cyclizine, haloperidol). NB: domperidone should be switched to metoclopramide parenteral If requiring regular dose: commence Haloperidol 1.5mg to 3mg SC in syringe pump (max 5mg/24hr) SC 2.5mg to 6.25mg 6 hourly (max 25mg/24hr) SC 2.5mg to 6.25mg 6 hourly (max 25mg/24hr) 2 nd line SC 2.5mg to 6.25mg once daily. Stop haloperidol (or other antiemetic) and prescribe 6.25mg to 12.5mg SC in syringe pump SC 2.5mg to 6.25mg 6 hourly (max 12.5mg PRN /24hr) Seek SPCT advice Avoid cyclizine in severe heart failure Avoid haloperidol and metoclopramide in Parkinson s Disease Persistent vomiting due to bowel obstruction: an NG tube, if tolerated, may be better than medication, but this would require inpatient admission. MOUTH CARE IN THE LAST DAYS OF LIFE Dry mouth and thirst are common symptoms in people who are dying. Good mouth care can help prevent thirst and maintain comfort. Patients should continue to be offered oral fluids. They may be able to manage sips even in the last days of life. Where patients can no longer manage oral fluids, staff must provide regular mouth care. Treatment Mouth care should be offered hourly, especially for patients who are unable to take oral fluids. Where possible family/carers can perform mouth care, giving them greater involvement. Clean mouth using water and a sponge stick (depending on local policy) or a soft toothbrush. Pineapple juice can be used to cleanse. Avoid lemon and glycerin swabs as they can increase dryness. Oxygen therapy may aggravate dry mouth. Consider whether this is still required, or whether it could be administered via nasal cannulae rather than a face mask. Consider humidification if on > 4L/28% via face mask. LIPS DRY DRY MOUTH SORE MOUTH /CRACKED 1 st Line Petroleum jelly (NB if patient on Biotene Oralbalance gel Gelclair apply directly, undiluted. oxygen use water based lubricant e.g. aquagel) 2 nd Line Glandosane spray Seek specialist palliative care advice. Review September
5 BREATHLESSNESS A table or handheld fan should be tried, and a more upright position can help. Explanation / reassurance and promoting a calm environment is important Consider relaxation techniques (if appropriate) Oxygen may relieve distress even if the patient is not hypoxic. Try 2-4 l/min via nasal cannula unless contraindicated. If there are signs of Pulmonary Oedema, consider need for diuretics (e.g. Furosemide 40mg SC / IV) or seek advice from SPCT Intermittent Breathlessness and /or distress Persistent distressing breathlessness Midazolam SC 2.5mg to 5mg hourly, PRN as required or Lorazepam sublingual 500mcg to 1mg, 4-6 hourly, PRN as required. Opioid (hourly as required) if on regular opioid use the appropriate breakthrough dose for pain or breathlessness (1/6 th of the total 24 hour dose) if no opioid try morphine PO 2.5mg to 5mg PRN or morphine SC 2.5mg (see opioid conversion guidance page 3) If on regular oral opioid or benzodiazepine, convert to a 24hour SC syringe pump (seek SPCT advice if unsure) If has required 2 or more doses in previous 24 hours, consider prescribing syringe pump over 24 hours e.g. Midazolam SC 5mg to 20mg (dependent on individual need) + morphine SC 5mg to 10mg (if no previous opioid use) RESPIRATORY TRACT SECRETIONS Terminal secretions can be controlled in about 60% of cases; fluid overload, recent aspiration and respiratory infection increase the incidence. Reduce the risk by avoiding fluid overload; if symptoms develop review any artificial hydration / nutrition (IV/SC fluids, feeding). Any changes to artificial hydration /feeding should be carefully discussed with family, explaining clearly the rationale for treatment withdrawal. Explain cause of problem to family /carers and any changes to management Changing the patient s position may help. Oropharyngeal suction is rarely beneficial 1st line: PRN Hyoscine butylbromide (Buscopan) SC 20mg, PRN hourly as required (max. dose 120mg/24 hrs). 24 hr Syringe Pump If PRN beneficial, consider Hyoscine Bultylbromide 60mg via syringe pump (max dose 120mg /24 hrs) 2nd line Glycopyrronium bromide SC 200micrograms, PRN hourly as required (max. dose 1.2mg/24 hrs) Seek specialist If symptoms are still troublesome consider if there are signs of pulmonary oedema and need for diuretics e.g. Furosemide 20-40mg SC / IV. (Note: max 20mg/2ml as SC injection) Review September
6 ACUTE & DISTRESSING TERMINAL EVENTS Dying patients occasionally develop acute distress; this can be due to: Bleeding: catastrophic haemorrhage from the GI or respiratory tract, or an external tumour ACUTE pain: bleeding into a solid tumour, a fracture, or a ruptured organ. ACUTE respiratory distress, tracheal obstruction Management Where it is possible to anticipate this could be an issue, agree an anticipatory care plan with the patient, if possible, family carers and key professionals For severe acute pain or respiratory distress give stat dose of breakthrough opiate sc. Please note that higher doses may be required. If symptoms do not respond, double the previous PRN dose and seek specialist promptly. For catastrophic haemorrhage prescribe sedation e.g. Midazolam 5mg to 10mg IM stat dose in advance if the patient is at risk; warn the family. WHAT CAN BE STOPPED? MANAGING COMORBIDITIES IN LAST DAYS OF LIFE DIABETES AND INSULIN When a patient is dying imminently and focus of care is solely symptomatic decisions should be made regarding diabetes management given that oral intake is likely to be minimal. Discuss changing approach to diabetes management with patient and/or family, if not already explored. Seek advice from Diabetic Specialists if unsure Type 1 diabetes Type 2 diabetes Insulin should be continued in these patients Simplify insulin regime ideally once daily long-acting insulin e.g. Lantus or Humulin I at a reduced equivalent dose. Check capillary blood glucose (CBG) once a day prior to giving insulin Aim to run CBG 8-15mmols. (Priority is to prevent hypoglycaemia) 1. If below 8mmols/l reduce insulin by 10-20% 2. If above 20mmols/l increase insulin by 10-20% to reduce risk of symptoms or ketoacidosis Aim to stop capillary blood glucose monitoring and stop/reduce diabetic medication If unresolved symptoms that may be attributable to hyperglycaemia consider urinalysis, if glucose 2+ check CBG and seek advice from SPCT or Diabetic Specialists EPILEPSY AND ANTI-SEIZURE MEDICATION At the end of life, once the patient can no longer take oral medication required to prevent seizures, their seizures should be prevented with subcutaneous midazolam: Prescribe midazolam 20mg to 30mg over 24 hours via SC syringe pump (the diluent is water) and midazolam 5mg to 10mg PRN SC An alternative for patients on oral Levetiracetam is to convert to a SC infusion i.e. 1:1 ratio, seek advice from SPCT If the SC route is not readily available for PRN use (e.g. the patient is in their own home), alternatives include: diazepam rectal (PR) enema (0.5mg/Kg up to a maximum dose of 30mg PRN) buccal midazolam (BuccolamTM) 10mg PRN sublingually Increase the syringe pump dose if PRN doses are needed and effective If seizures persist despite midazolam 60mg/24hrs via SC syringe pump, seek advice from SPCT Review September
7 WHAT CAN BE STOPPED? MANAGING COMORBIDITIES IN LAST DAYS OF LIFE CORTICOSTEROIDS Steroids not contributing to symptom relief Steroids contributing to symptom relief (i.e. symptoms likely to recur if stopped such as severe headaches or vomiting after cerebral bleed) CARDIOVASCULAR CONDITIONS Angina Hypertension Heart Failure Stop at the end of life when the oral route is no longer available. If the dying process is already established, Addisonian withdrawal effects are not usually relevant. Convert to a subcutaneous (SC) bolus of dexamethasone each morning. Seek SPCT advice if unsure Medication can usually be discontinued without substituting an alternative once the patient is unable to take orally. The minimal exertion at the end of life minimises the risk of angina occurring. If angina symptoms are suspected, or there is particular concern, consider symptomatic management with opioids and seek advice from SPCT Antihypertensives should be discontinued in the last days of life and can often be stopped before then. Statins can be stopped if the prognosis is less than 1 year Mild-moderate: medication usually discontinued without substituting an alternative once the patient is unable to take orally because of the minimal fluid intake at this stage. Severe (e.g. the patient is dying from end-stage heart failure), then consider: Subcutaneous furosemide. Usually given as a SC bolus OD or BD or via SC 24 hours syringe pump: Seek advice from SPCT Opioids (See Breathlessness section page 6) NEUROLOGICAL CONDITIONS Parkinsons Disease Consider giving medication via an alternative route e.g. topical patch. Seek specialist. Unlicensed Use of Licensed Medicines ( Off label use) Use of drugs in these guidelines and their routes of administration are outside their product licences Off Label The unlicensed use of medicines is necessary when clinical need cannot be met by the licensed medicines available. The recommendations in this guide do include unlicensed use of licensed medicines. These recommendations are based on current accepted palliative care practice in the UK. In practice, approximately 25% of prescribed medicines for palliative care patients are used in an unlicensed way (e.g. given by subcutaneous injection when licensed for IM or IV use, or for the treatment of nausea and vomiting when only licensed as an antipsychotic). Further information regarding unlicensed use of individual palliative care medicines can be found in the current version of the Palliative Care Formulary Disclaimer: These guidelines are the property of the Bradford, Airedale, Wharfedale and Craven Managed Clinical Network for Palliative Care Group. It is intended that they be used by qualified medical and other healthcare professionals as an information resource, in the clinical context of each individual patient s needs. The BAWC take no responsibility for any consequences of any actions taken as a result of using these guidelines. Readers are strongly advised to ensure they are acting in keeping with current accepted practice and legislation, as these may change. No legal liability is accepted for any errors in these guidelines, or for the misuse or misapplication of the advice presented here. In difficult situations, please seek advice from the relevant specialist palliative care service. Review September
Care in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More informationMMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life
MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationSymptom Management Guidelines for End of Life Care
Symptom Management Guidelines for End of Life Care The following pages are guidelines for the management of common symptoms in the last few days of life. General principles: 1. Consider how symptoms can
More informationSupportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
More informationAlgorithms for Symptom Management. In End of Life Care
Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More informationSYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL
SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL If a patient is believed to be approaching the end of their life, medication should be prescribed in anticipation
More informationSyringe driver in Palliative Care
Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24
More informationCare of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.
Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients
More informationAnticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO
Anticipatory Medications for End of Life Patients oses must be proportional to the current analgesic medication Please refer ALL patients on Methadone or Ketamine to palliative care team for advice. Patients
More informationEnd of life prescribing guidance
End of life prescribing guidance Introduction This guidance has been prepared to ASSIST IN DECISION MAKING for the prescribing and monitoring of medicines useful in the management of symptoms commonly
More informationGuidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)
Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth) Policy Number : DC020 Issue Date: October 2014 Review date: October 2016 Policy Owner: Head Community Services Monitor:
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early recognition of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More informationRenal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life
Guidance for Anticipatory prescribing for patients in renal failure (egfr
More informationPalliative care for heart failure patients. Susan Addie
Palliative care for heart failure patients Susan Addie Treatments The most common limiting and distressing complaint is of fatigue and breathlessness. Optimal treatment strategies relieve symptoms, improves
More informationANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT
ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL Doses of opiates must be proptional to current analgesic medication Please refer ALL patients on Methadone Ketamine to SPCT f advice. Patients
More informationThe last days of life in hospital and at home
The last days of life in hospital and at home Beaumont Multi-disciplinary Palliative Care Study Day 28/9/2017 Dr Sarah McLean Consultant in Palliative Medicine St Francis Hospice Beaumont Hospital Overview
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More information[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]
[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text] Patients with egfr greater than 30mL/min Patients with egfr less than 30mL/min Symptom Drug Dose Symptom Drug Dose
More informationDoncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary
Doncaster & Bassetlaw Cancer Locality Palliative Core Formulary Approved by Doncaster & Bassetlaw Hospitals NHS Foundation Trust Drugs and Therapeutics Committee. DJ14/2155 Oct 2014 Review date: Oct 2017
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationCare of dying adults in the last days of life. Improving care at the very end of life.
Care of dying adults in the last days of life Improving care at the very end of life. Foreword We will all experience death, whether it is our own or that of a loved one. The bereaved person s perception
More informationPalliative Care Impact Survey
September 2018 Contents Introduction...3 Headlines...3 Approach...4 Findings...4 Which guideline are used...4 How and where the guidelines are used...6 Alternative sources of information...7 Use of the
More informationImplementing the recommendation on medication management and symptom control
Implementing the recommendation on medication management and symptom control Mike Grocott Professor of Anaesthesia and Critical Care Medicine University of Southampton Consultant in Critical Care Medicine
More informationConservative Management of Uraemia
Conservative Management of Uraemia Information for Health Professionals Renal Department The York Hospital and Scarborough Hospital Tel: 01904 725370 For more information, please contact: The Renal Specialist
More informationGUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)
GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT These guidelines have been produced in collaboration with Dr Lucy Smyth, Consultant in Renal Medicine, Royal Devon and Exeter
More informationEAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE
EAST LANCASHIRE SPECIALIST PALLIATIVE CARE TEAM EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE Reviewed and updated August 2009 Next review date August 2011 Approved
More informationIn our patients the cause of seizures can be broadly divided into structural and systemic causes.
Guidelines for the management of Seizures Amalgamation and update of previous policies 7 (Seizure guidelines, ND, 2015) and 9 (Status epilepticus, KJ, 2011) Seizures can occur in up to 15% of the Palliative
More informationBJF Acute Pain Team Formulary Group
Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution
More informationApproach to symptom control near the end-of-life
Approach to symptom control near the end-of-life 18 Sept 2011 Dr Alethea Yee Senior Consultant, Department of Palliative Medicine National Cancer Centre,Singapore What is end of life? No precise definition
More informationManaging Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.
Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital. Things to consider: 1. Very common symptoms. 2. Can occur in any
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationSYRINGE DRIVER MEDICATIONS
SYRINGE DRIVER MEDICATIONS Christine Hull & Anita Webb Staff Nurses, Hospice in the Home 2015 Analgesics:- Groups of Medication used in Syringe Drivers Morphine sulphate Diamorphine Oxycodone Alfentanil
More informationAnticipatory prescribing and end of life considerations. Dr Stephanie Lippett
Anticipatory prescribing and end of life considerations Dr Stephanie Lippett contents Pain Restlessness/agitation Nausea/vomiting Secretions Syringe driver Anticipatory prescribing Important things to
More informationDiamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30
If more information is required please seek help from specialist palliative care pioid dose conversion chart, syringe driver doses, rescue/prn doses and opioid patches Use the conversion chart to work
More informationPalliative care for patients with brain cancer
Palliative care for patients with brain cancer Lyn Cave Clinical Nurse Specialist Palliative Care Hospital2Home (H2H) Dr Jayne Wood Clinical Lead Palliative Care The Royal Marsden and Royal Brompton Palliative
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationAnalgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-
Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the
More informationPENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE
PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE Originally produced: July 2006 First Review: August 2009 Second Review: November 2011 For review November 2013 Approved
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More information1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER
1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER 1.1 GENERAL PRINCIPLES There are many causes of agitation in palliative care patients, which makes recommendations for treatment difficult.
More informationRegional Renal Training
Regional Renal Training Palliative and End of Life Care Dr Clare Kendall North Bristol NHS Trust Advanced Kidney Disease Dialysis/Transplant Conservative Management Deteriorating despite dialysis/failing
More informationPalliative Care. Pocketbook 4
Nottinghamshire STP EOL Programme Board 2019 Review 2022 Palliative Care Pocketbook 4 Contents Pain Guidelines page 2 Nausea and Vomiting page 9 Inoperable Bowel Obstruction page 10 Constipation page 11
More informationEnd Stage Liver Disease Regional Audit Casenote Survey
1. This questionnaire is an audit of clinical documentation of patients who have died of end stage liver disease. If you have any questions about how this form should be completed please contact Dr Grace
More informationNorth Wales Critical Care Network
North Wales Critical Care Network SEDATION GUIDELINES FOR ADULTS IN CRITICAL CARE Approved 6.9.12 1 Sedation guidelines for intensive care Betsi Cadwaladr University Health Board (Adapted from guidelines
More informationMND Just in Case kit Information for GPs
MND Just in Case kit Information for GPs What is the MND Just in Case kit? 2 Motor neurone disease (MND) is a progressive and terminal disease that results in degeneration of the motor neurones in the
More informationPalliative care in long-term conditions Scottish Palliative Care Pharmacists Association
Palliative care in long-term conditions 2011 2012 Scottish Palliative Care Pharmacists Association Aims & Objectives To explore symptoms, general management principles and appropriate palliative treatment
More informationBerkshire Adult Palliative Care Guidelines - End of Life Care GL110
Berkshire Adult Palliative Care Guidelines - End of Life Care GL110 Approval Approval Group Job Title, Chair of Committee Date Drugs & Therapeutic Committee Chair, Drugs & Therapeutic Committee October
More informationPalliative Care Out-of-hours. A resource pack for West Dorset. Contents:
Palliative Care Out-of-hours. A resource pack for West Dorset Contents: Section 1 Supply of drugs DCH Pharmacy hours and arrangements How to contact a community pharmacist out of hours Palliative care
More informationSpecialist Palliative Care Audit and Guidelines Group (SPAGG)
Specialist Palliative Care Audit and Guidelines Group (SPAGG) Clinical Guideline for the Prescribing and Administration of Furosemide via continuous subcutaneous infusion (CSCI) for Heart Failure Patients
More informationWaterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)
Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC) May 2018 THE WATERLOO WELLINGTON SYMPTOM MANAGEMENT GUIDELINE FOR THE END OF
More informationSUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:
FILE IN PATIENT S COMMUNITY HEALTH RECORD FOLDER : SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRERIPTION & ADMINISTRATION RECORD (SPAR) Abbreviations used in this document to be listed here with the full
More informationWe would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.
We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients. The closing date for responses is 19th December The results
More informationsurvey Parenteral anti-epileptics What is your experience? May July 2015
Parenteral anti-epileptics What is your experience? May July 2015 Number of responses = 99 1a) In patients with pre-existing epilepsy controlled by PO medication that are imminently dying (prognosis
More informationSymptom Control in the Community Setting. Dr Andrew Tysoe-Calnon
Symptom Control in the Community Setting Dr Andrew Tysoe-Calnon Lead Consultant t Common symptoms Pain Agitation Shortness of breath Nausea and vomiting Intestinal obstruction Confusion Pain Occurs in
More informationUsing syringe pumps in palliative care
Using syringe pumps in palliative care Facilitator: Barbara Stone RN Ground rules Medication matching game Learning outcomes To identify the indications for using a syringe pump To discuss the general
More informationPalliative Care Emergencies. Additional module if needed
Palliative Care Emergencies Additional module if needed Learning objectives Understand emergency /urgent / important Describe common emergencies in PC Explore principles of essential management Outline
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationPain management in Paediatric Palliative Care. Dr Jane Nakawesi 14 th August 2017
Pain management in Paediatric Palliative Care Dr Jane Nakawesi 14 th August 2017 Content Management of pain in children Non pharmacological Pharmacological Exit level outcomes The participants will: Know
More informationThe last days of life Linda Magann CNC Palliative Care St George Hospital I m not afraid of dying, I just don t want to be there when it happens Woody Allen Palliative Care is an approach that improves
More informationCare of the dying in End Stage Kidney Disease (ESKD) - Conservative. Elizabeth Josland Renal Supportive Care CNC St George Hospital
Care of the dying in End Stage Kidney Disease (ESKD) - Conservative Elizabeth Josland Renal Supportive Care CNC St George Hospital Introduction What does conservative management look like? How does the
More informationCLINICAL GUIDELINES FOR END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES
CLINICAL GUIDELINES F END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES OPENING STATEMENT: Insert Facility Name is committed to providing effective end-of-life symptom management to all residents. Symptom
More informationLothian Palliative Care Guidelines POCKET EDITION 2004
Lothian Palliative Care Guidelines POCKET EDITION 2004 These guidelines have been developed by a multidisciplinary group of specialist and non-specialist health professionals from hospital, community and
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationBREATHLESSNESS MANAGEMENT
Guideline Name: Breathlessness BACKGROUND Breathlessness is a common symptom in patients with cancer, end-stage heart failure and end-stage chronic obstructive pulmonary disease (COPD). There are many
More informationAnalgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
More informationCARE OF THE DYING PATIENT WITH ESKD ELIZABETH JOSLAND - RSC CNC
CARE OF THE DYING PATIENT WITH ESKD ELIZABETH JOSLAND - RSC CNC OBJECTIVES UNDERSTANDING OF: POTENTIAL COMPLEXITIES OF ESKD PATIENTS IMPORTANCE OF COMMUNICATION CONSIDERATIONS AT END-OF-LIFE END-OF-LIFE
More informationGuidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).
Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Guidelines for the
More informationOpioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.
Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient
More informationUnderstanding pain in 5 minutes
Pain Management- PallCare Definition of Pain Pain is what the patient says hurts. Dr Simon Allan Director of Palliative Care Arohanui Hospice An unpleasant sensory and emotional experience associated with
More informationAcute painful crisis in patients with sickle cell disease: Clinical Guidelines (HN-506a)
Acute painful crisis in patients with sickle cell disease: Clinical Guidelines (HN-506a) Introduction The majority of acute painful crises in patients with sickle cell disease will be managed independently
More informationCONTROLLED DOCUMENT. Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) Controlled Document Number: CG259
Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: Controlled Document Number: Version Number: 1 Controlled Document Sponsor:
More informationQ&A: Opioid Prescribing for Chronic Non-Malignant Pain
NHS Hastings and Rother Clinical Commissioning Group Chair Dr David Warden Chief Officer Amanda Philpott NHS Eastbourne, Hailsham and Seaford Clinical Commissioning Group Chair Dr Martin Writer Chief Officer
More informationEnd of Life Care. Dr Anne Garry Consultant in Palliative Medicine
End of Life Care Dr Anne Garry Consultant in Palliative Medicine Concerns voiced both by public and professionals.. Implementation and on-going training highly variable across country Decisions made by
More informationPalliative Care Formulary
Palliative Care Formulary 2016-2019 This formulary for pain and symptom management in adults is intended as a guide for prescribers in hospital and community. Special care should be taken when prescribing
More informationADULT (>16) ACUTE SICKLE PAIN GUIDELINE
ADULT (>16) ACUTE SICKLE PAIN GUIDELINE ID 2013 065 Author s Name Dr Anna Wood Author s Job Title Consultant Haematologist Division Consultant Haematologist Department Haematology Version number 3 Ratifying
More informationSyringe Drivers. Back to top
Page 1 of 8 Syringe Drivers Introduction Indications for use Advantages Method Siting syringe driver Boost facility Transfer to hospital/hospice syringe driver drugs Drug compatibility P.r.n medication
More informationTarget audience: The target audience for this guidance are: GPs Care home managers and nurses, District nurses, and Specialist Palliative Care teams.
Anticipatory medication guidance for the last days of life for frail older people being care for in care homes who do not have Specialist Palliative Care needs Purpose of guidance: The purpose of this
More informationLong Term Care Formulary HCD - 08
1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally
More informationThis survey aims to look at individual practice and can be completed by any healthcare professional.
This survey aims to look at individual practice and can be completed by any healthcare professional. If you have any questions about how this form should be completed please contact Dr Grace Ting (ghlting@doctors.net.uk)
More informationSymptom Management Challenges at End-of-Life
Symptom Management Challenges at End-of-Life Amanda Lovell, PharmD, BCGP Clinical Pharmacist- Inpatient Units Optum Hospice Pharmacy Services February 15, 2018 Hospice Pharmacy Services Objectives Identify
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationVentilation/End of Life Neuromuscular Disorders. Dr Emma Husbands Consultant Palliative Medicine
Ventilation/End of Life Neuromuscular Disorders Dr Emma Husbands Consultant Palliative Medicine Emma.Husbands@glos.nhs.uk Contents Cases NIV and palliation and ethical bits APM guidelines Important bits
More informationWhat s New 2003? What new treatments? What have you discontinued? More information please!
What s New 2003? What new treatments? What have you discontinued? More information please! 1 What s New 2003? Submissions = 137 UK = 52 (38%) Doctors = 60% Nurses = 25% Pharmacists = 15% 2 What s New?
More informationNHS Grampian. Care Plan Palliative & Supportive. Acute Care Settings
NHS Grampian Palliative & Supportive Care Plan 2013 Acute Care Settings Contents Page 1. Introduction 2. Standards 3. The identification of the palliative patient 4. Assessment of the palliative patient
More informationManaging dying with chronic heart failure
Heart failure Managing dying with chronic heart failure Chronic heart failure (CHF) is predominantly a pathology of old age affecting 5% of those over 75 years of age. It is more common than cancer and
More informationGG&C Chronic Non Malignant Pain Opioid Prescribing Guideline
GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline Background Persistent pain is common, affecting around five million people in the UK. For many sufferers, pain can be frustrating and disabling,
More informationA Brief Guide to Symptom Management and End of Life Care for Children During Pandemic Influenza
A Brief Guide to Symptom Management and End of Life Care for Children During Pandemic Influenza Background This guidance is intended ONLY for use in situations where health services are overwhelmed and
More informationINTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT
INTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT PLEASE INFORM THE PALLIATIVE CARE TEAM ON COMMENCEMENT OF THIS ICP (EXT 8958) ICP Start Date Patient s Name. Ward. Consultant.. Named Specialist Nurse
More informationPALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS
PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS Background information Substance misusers who develop palliative care needs are likely to have psychological, social and existential
More informationDelirium. Assessment and Management
Delirium Assessment and Management Goals and Objectives Participants will: 1. be able to recognize and diagnose the syndrome of delirium. 2. understand the causes of delirium. 3. become knowledgeable about
More informationPRIMARY CARE PALLIATIVE CARE FORMULARY
PRIMARY CARE PALLIATIVE CARE FORMULARY National Institute for Health and Care Excellence (NICE) guidance NG31 (Care of dying adults in the last days of life) supports the need to prescribe anticipatory
More information